Biological products or biologics are
therapeutic preparations that consist of natural complex biomolecules
derived from living things. Active pharmaceutical ingredients (API),
vaccines serum, and hematological products (whole blood and plasma
derivatives), recombinant DNA products, cell cultures (micro-organisms
or eukaryotic cells), gene therapy and cell therapy products, antigens,
allergens, antivenoms, etc. are some examples of biological products.
Due to the recent advances in supply chain management and favorable
federal regulations, the biological products manufacturing industry has
become a lucrative market for startups, contractual manufacturing
companies, and strategic collaborations, equipped with skilled workers
and affordable pricing. Increase in investments for R&D by various
organizations, with an aim of manufacturing cost reduction and
economical yet sustainable biological product manufacturing are serving
as opportunities for many companies and collaborations in biological
product manufacturing industries.
Major market players in the global
biological product manufacturing market have various advantages such as
cutting edge technologies, superior research and development,
technologically advanced instruments, and skilled workforce to ensure
proper assembly and delivery of the product. The biological product
manufacturing market is driven by extensive R&D, along with
increasing demand from health care providers across the world for
advanced biological products, and growing focus by market players to
provide quality products. However, competitive costs of therapeutic
products, requirement of highly skilled labor for high value low volume
biological product manufacturing, limited availability foreign capital,
and stringent regulatory affairs regarding the manufacture of biological
products are restraining the global biological product manufacturing
market.
The global biological product
manufacturing market has been segmented based on product type, end-user,
application, and region. In terms of product type, the market is
classified into bio-pharmaceutical products and
biotechnological/biological products. The bio-pharmaceutical products
segment includes vaccines, immunoglobulins, serum and other blood
related product, allergens, antigens, antivenoms, and toxoids. The
biotechnological/biological products segment includes micro-organism or
eukaryotic cell culture, recombinant DNA technology products, gene
therapy product, and cell therapy product. The biopharmaceuticals
products segment accounted for the largest share of the global
biological product manufacturing market. Based on end-user, the
biological product manufacturing market has been segmented into
hospitals, research and academic institutes, clinics and specialty
trials, diagnostic labs, and others. The hospitals end-user segment
accounted for the largest share of the global biological product
manufacturing market, followed by research and academic institutes.
Superior technological advancements serve
as a major opportunity in the biological product manufacturing market.
Rising incidence of chronic diseases across the world, availability of
better diagnostic facilities, advances in the drug discovery and
pharmaceutical R&D sector, and rising government initiatives are
some of the factors attributed to the high growth of the biological
product manufacturing market. Increasing focus on discovery of heat
labile or temperature sensitive products, advanced biopharmaceutical
research in medicine, and invention of effective means to treat various
diseases are expected to boost the growth of the biological product
manufacturing market.
In terms of region, the global biological
product manufacturing market has been segmented into five regions:
North America, Europe, Asia Pacific, Latin America, and Middle East
& Africa. The market in Asia Pacific is projected to expand at a
higher CAGR during the forecast period driven by factors such as low
labor cost, less capital investment for manufacturing, increasing
adoptions of new techniques in manufacturing of biological product, and
favorable governmental policies. North America dominated the global
biological product manufacturing market in 2015 due to factors such as
new and technologically advanced products introduced in the market,
significant investments in research and development of advanced
products, and increasing patient demand for better health care
facilities.
Key players in the biological product
manufacturing market are Lonza, Advanced Life Sciences Holdings, Inc.,
Pfizer, Inc., Johnson & Johnson, Invitrogen, Amgen, Abbott
Laboratories, Piramal Healthcare, and Shenhua Group Corp. Ltd.
No comments:
Post a Comment